Idiopathic Pulmonary Fibrosis Registry for Future Studies

This study is currently recruiting participants.

Verified by Ohio State University, December 2008

Sponsored by:	Ohio State University
Information provided by:	Ohio State University
ClinicalTrials.gov Identifier:	NCT00815711

Purpose

To establish a registry olf patients for furutre studies of Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis.

Condition
Lung Disease, Interstitial Idiopathic Pulmonary Fibrosis

MedlinePlus related topics: Pulmonary Fibrosis

U.S. FDA Resources

Study Type:	Observational
Study Design:	Cohort, Prospective
Official Title:	Inflammation in Interstitial Lung Disease/Idiopathic Pulmonary Fibrosis

Further study details as provided by Ohio State University:

Biospecimen Retention: Samples With DNA

Biospecimen Description:

blood serum BAL fluid lung biopsy

Estimated Enrollment:	84
Study Start Date:	December 2008
Estimated Study Completion Date:	January 2015
Estimated Primary Completion Date:	January 2015 (Final data collection date for primary outcome measure)

Detailed Description:

To establish a framework in which biologic samples and physiologic measures from patients with IPF can be longitudinally collected and evaluated. Having a bank of samples that are correlated with physciologic measures that follow patients through their course will allow the followign proposed studies as well as future investigations to be efficiently carried out.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

primary care clinic

Criteria

Inclusion Criteria:

any patient referred to the Interstitial Lund Disease clinic who is undergoing evaluation and or treatment for a new diagnosis of ILD. This can include patients referred for presumed pulmonary fibrosis/interstitial pneumonitis (IPF, UIP, NSIP), sarcoidosis, hypersensitivity pneumonitis, cryptogenic organising pneumonia, drug-induced, or other idiopathic ILDs.

Exclusion Criteria:

pregnancy
inability to follow study requirements

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00815711

Contacts

Contact: Janice E Drake, CRTT	614-688-2287	janice.drake@osumc.edu
Contact: Sharon T Cheung, BS	614-366-2258	sharon.cheung@osumc.edu

Locations

United States, Ohio
The Ohio State University	Recruiting
Columbus, Ohio, United States, 43210
Contact: Janice E Drake, CRTT
Sub-Investigator: James N Allen, MD
Sub-Investigator: Nitin Y Bhatt, MD
Sub-Investigator: Christopher Baran, PhD

Sponsors and Collaborators

Ohio State University

Investigators

Principal Investigator:

Clay B Marsh, MD

Ohio State University

More Information

Responsible Party:	The Ohio State University ( Clay Marsh, MD )
Study ID Numbers:	2007H0002
Study First Received:	December 29, 2008
Last Updated:	December 29, 2008
ClinicalTrials.gov Identifier:	NCT00815711
Health Authority:	United States: Institutional Review Board

Keywords provided by Ohio State University:

IPF

Study placed in the following topic categories:

Lung Diseases, Interstitial
Respiratory Tract Diseases
Fibrosis
Hamman-Rich syndrome

Lung Diseases
Pulmonary Fibrosis
Inflammation

Additional relevant MeSH terms:

Pathologic Processes

ClinicalTrials.gov processed this record on January 15, 2009